Advertisement Covers IAS 2015


Post-Treatment Controllers: Pathway to a Functional Cure?

August 10, 2015

Dr. Mirko Paiardini (Photo copyright Steve Forrest/Worker's Photos/IAS)

Dr. Mirko Paiardini (Photo copyright Steve Forrest/Worker's Photos/IAS)

Recent reports of a French teenager in remission from her HIV infection for 12 years serve as an important reminder that a functional cure for HIV is attainable. This case, presented at the International AIDS Society (IAS) conference in Vancouver, represents the longest reported instance of remission. Other cases of remission have also been reported and seem to be an outcome associated with between 5% and 15% of HIV-infected persons who start combination antiretroviral therapy (cART) early during acute infection.

These patients, known as post-treatment controllers (PTCs), are different than elite controllers, the roughly 1% of HIV-positive individuals who are able to control their HIV infection to undetectable levels without the use of antiretroviral therapy. The majority of HIV-positive individuals can only manage their viral load with the use of cART. Once the drugs are stopped, HIV comes roaring back and is readily detectable in their blood. PTCs, however, are able to control their HIV infection even when treatment is stopped. Starting cART early seems to be the key to their immunologic control, but how exactly their bodies are able to lock down HIV is an area of active investigation.

Mirko Paiardini, an amfAR-funded investigator at Emory University in Atlanta, is trying to solve this mystery by establishing an animal model to study PTCs. Dr. Paiardini presented data at the IAS conference that described a primate model mirroring the virologic and immunologic features of human PTCs. Animal models are crucial to understanding the biological mechanisms at work in PTCs and can contribute to our understanding of how a functional cure might be achieved in humans.

Dr. Paiardini's amfAR-funded studies also aim to address whether the latent viral reservoir can be diminished by treatment with the immune modulator, IL-21. This viral reservoir is the single most important bottleneck that has prevented a cure for HIV and is the reason for HIV's resurfacing in the majority of patients following cessation of cART. If Dr. Paiardini's work succeeds in establishing IL-21's role in shrinking the viral reservoir, we will certainly be one step closer to a cure.

Dr. Flores is amfAR's associate director of research.

Related Stories

No Proof of New HIV Cure, Despite Headlines -- Here's What We Know
The Only Cases of HIV Cure or Remission
Beyond the Berlin Patient: How Researchers Are Now Trying to Cure More HIV-Positive People (Video)
What Would an HIV Cure Mean for You?

This article was provided by amfAR, The Foundation for AIDS Research. Visit amfAR's website to find out more about their activities and publications.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.